RT Journal Article
SR Electronic
T1 Convergent coexpression of autism associated genes suggests some novel risk genes may not be detectable in large-scale genetic studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.28.22271620
DO 10.1101/2022.02.28.22271620
A1 Liao, Calwing
A1 Moyses-Oliveira, Mariana
A1 De Esch, Celine EF
A1 Bhavsar, Riya
A1 Nuttle, Xander
A1 Li, Aiqun
A1 Yu, Alex
A1 Burt, Nicholas D.
A1 Erdin, Serkan
A1 Fu, Jack M.
A1 Wang, Minghui
A1 Morley, Theodore
A1 Han, Lide
A1 ,
A1 Dion, Patrick A.
A1 Rouleau, Guy A.
A1 Zhang, Bin
A1 Brennand, Kristen J.
A1 Talkowski, Michael E.
A1 Ruderfer, Douglas M.
YR 2022
UL http://medrxiv.org/content/early/2022/08/11/2022.02.28.22271620.abstract
AB Autism spectrum disorder (ASD) is a highly heritable neurodevelopmental disorder characterized by deficits in social interactions and communication. Protein function altering variants in many genes have been shown to contribute to ASD risk; however, understanding the biological convergence across so many genes has been difficult and genetic studies depending on presence of deleterious variation may be limited in implicating highly intolerant genes with shorter coding sequences. Here, we demonstrate that coexpression patterns from human post-mortem brain samples (N = 993) are significantly correlated with the transcriptional consequences of CRISPR perturbations (gene editing, interference and activation) in human neurons (N = 17). Across 71 ASD risk genes, there is significant tissue-specific transcriptional convergence that implicates synaptic pathways. Tissue specific convergence of risk genes is a generalizable phenomenon, shown additionally in schizophrenia (brain) and atrial fibrillation (heart). The degree of this convergence in ASD is significantly correlated with the level of association to ASD from sequencing studies (rho = -0.32, P = 3.03 ×10−65) as well as differential expression in post-mortem ASD brains (rho = -0.23, P = 2.39×10−43). After removing all genes statistically associated with ASD, the remaining positively convergent genes showed intolerance to functional mutations, had shorter coding lengths than the ASD genes and were enriched for genes with clinical reports of potential pathogenic contribution to ASD. These results indicate that leveraging convergent coexpression can identify potentially novel risk genes that are unlikely to be discovered by sequencing studies. Overall, this work provides a simple approach to functionally proxy CRISPR perturbation, demonstrates significant context-specific transcriptional convergence among known risk genes of multiple diseases, and proposes novel ASD risk gene candidates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC.L. was supported by a Vanier Graduate Scholarship from the Canadian Institutes of Health Research (CIHR). M.M.O. and J.M.F. were supported by Autism Speaks Foundation Postdoctoral Fellowships (#11815 and #11852, respectively). X.N. was supported by F32MH115614) and K99MH121577. G.A.R. was supported by a CIHR Foundation Scheme grant (#332971). This work was also supported by R01MH123155 (DMR, KJB, MET), R01HD096326 (MET), R01NS093200 (MET), R01MH111776 (DMR), and the Simons Foundation for Autism Research (#573206 to MET). Data were generated as part of the CommonMind Consortium supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH- 075916, P50M096891, P50MH084053S1, R37MH057881, AG02219, AG05138, MH06692, R01MH110921, R01MH109677, R01MH109897, U01MH103392, U01MH116442, project ZIC MH002903 and contract HHSN271201300031C through IRP NIMH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research abided by ethical regulations and was approved by the Vanderbilt University Medical Center Review Board (IRB: 220287).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNearly all data are publicly available and sources are described in the manuscript. The few that are not will be made publicly available but earlier access can be made available on request.